RadNet, Inc. (RDNT)
USD 72.41
(-5.37%)
USD 72.41
(-5.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 292.78 Million USD | 16.2% |
| 2022 | 278.53 Million USD | -8.16% |
| 2021 | 278.37 Million USD | 27.31% |
| 2020 | 199.73 Million USD | -9.26% |
| 2019 | 225.16 Million USD | 44.4% |
| 2018 | 107.59 Million USD | 18.77% |
| 2017 | 119.8 Million USD | 10.33% |
| 2016 | 108.73 Million USD | 7.07% |
| 2015 | 116.94 Million USD | -8.72% |
| 2014 | 114.91 Million USD | 12.35% |
| 2013 | 104.33 Million USD | 2.28% |
| 2012 | 108.5 Million USD | 1.83% |
| 2011 | 105.9 Million USD | 13.18% |
| 2010 | 81.13 Million USD | 0.42% |
| 2009 | 85.37 Million USD | 7.3% |
| 2008 | 86.83 Million USD | 30.6% |
| 2007 | 67.52 Million USD | 85.1% |
| 2006 | 32.66 Million USD | 18.11% |
| 2005 | 30.93 Million USD | 4.8% |
| 2004 | 29.01 Million USD | -0.2% |
| 2003 | 29.3 Million USD | 10.09% |
| 2002 | 25.19 Million USD | 1.16% |
| 2001 | 28.64 Million USD | 11.27% |
| 2000 | 23.37 Million USD | 97.18% |
| 1999 | 9.9 Million USD | 396.23% |
| 1998 | -7.86 Million USD | 69.11% |
| 1997 | 1.77 Million USD | -515.66% |
| 1996 | 4.2 Million USD | 107.02% |
| 1995 | -44.15 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 58.82 Million USD | -35.85% |
| 2024 Q2 | 69.99 Million USD | 58.64% |
| 2023 FY | - USD | 16.2% |
| 2023 Q1 | 54.39 Million USD | -2.96% |
| 2023 Q3 | 98.24 Million USD | 29.52% |
| 2023 Q4 | 77.35 Million USD | -21.27% |
| 2023 Q2 | 75.85 Million USD | 39.45% |
| 2022 Q2 | 68.6 Million USD | 49.53% |
| 2022 Q4 | 56.05 Million USD | 1.37% |
| 2022 Q3 | 55.29 Million USD | -19.4% |
| 2022 FY | - USD | -8.16% |
| 2022 Q1 | 45.88 Million USD | 32.63% |
| 2021 Q4 | 34.59 Million USD | -57.81% |
| 2021 Q1 | 59.22 Million USD | 11.55% |
| 2021 Q2 | 70.82 Million USD | 19.58% |
| 2021 FY | - USD | 27.31% |
| 2021 Q3 | 81.99 Million USD | 15.78% |
| 2020 Q4 | 53.09 Million USD | -17.84% |
| 2020 Q3 | 64.62 Million USD | 62.71% |
| 2020 Q2 | 39.71 Million USD | 19.08% |
| 2020 FY | - USD | -9.26% |
| 2020 Q1 | 33.35 Million USD | -31.49% |
| 2019 Q3 | 57.27 Million USD | -5.26% |
| 2019 Q2 | 60.45 Million USD | 30.38% |
| 2019 Q1 | 46.36 Million USD | -29.13% |
| 2019 FY | - USD | 44.4% |
| 2019 Q4 | 48.68 Million USD | -15.0% |
| 2018 Q4 | 65.42 Million USD | 79.49% |
| 2018 FY | - USD | 18.77% |
| 2018 Q1 | 18.73 Million USD | -53.8% |
| 2018 Q2 | 38.08 Million USD | 103.28% |
| 2018 Q3 | 36.45 Million USD | -4.28% |
| 2017 Q2 | 34.39 Million USD | 33.64% |
| 2017 Q4 | 40.55 Million USD | 23.09% |
| 2017 Q3 | 32.94 Million USD | -4.2% |
| 2017 Q1 | 25.73 Million USD | -25.19% |
| 2017 FY | - USD | 10.33% |
| 2016 FY | - USD | 7.07% |
| 2016 Q1 | 24.64 Million USD | -18.9% |
| 2016 Q2 | 27.77 Million USD | 12.68% |
| 2016 Q3 | 34.29 Million USD | 23.48% |
| 2016 Q4 | 34.4 Million USD | 0.31% |
| 2015 FY | - USD | -8.72% |
| 2015 Q2 | 31.28 Million USD | 87.11% |
| 2015 Q3 | 34.71 Million USD | 10.97% |
| 2015 Q4 | 30.39 Million USD | -12.47% |
| 2015 Q1 | 16.72 Million USD | -46.51% |
| 2014 Q2 | 32.92 Million USD | 23.44% |
| 2014 Q1 | 26.67 Million USD | -14.92% |
| 2014 FY | - USD | 12.35% |
| 2014 Q4 | 31.25 Million USD | -5.45% |
| 2014 Q3 | 33.06 Million USD | 0.42% |
| 2013 Q1 | 23.38 Million USD | -9.64% |
| 2013 FY | - USD | 2.28% |
| 2013 Q4 | 31.35 Million USD | 25.24% |
| 2013 Q2 | 29.33 Million USD | 25.45% |
| 2013 Q3 | 25.03 Million USD | -14.66% |
| 2012 Q4 | 25.87 Million USD | -4.75% |
| 2012 Q1 | 26.16 Million USD | -18.55% |
| 2012 Q2 | 28.63 Million USD | 9.43% |
| 2012 Q3 | 27.16 Million USD | -5.13% |
| 2012 FY | - USD | 1.83% |
| 2011 Q2 | 27.26 Million USD | 22.03% |
| 2011 FY | - USD | 13.18% |
| 2011 Q4 | 32.12 Million USD | 32.9% |
| 2011 Q3 | 24.17 Million USD | -11.32% |
| 2011 Q1 | 22.33 Million USD | -19.54% |
| 2010 FY | - USD | 0.42% |
| 2010 Q3 | 24.38 Million USD | 2.5% |
| 2010 Q1 | 17.73 Million USD | -28.08% |
| 2010 Q2 | 23.79 Million USD | 34.19% |
| 2010 Q4 | 27.76 Million USD | 13.85% |
| 2009 Q2 | 22.44 Million USD | -2.41% |
| 2009 FY | - USD | 7.3% |
| 2009 Q1 | 22.99 Million USD | 15.1% |
| 2009 Q4 | 24.65 Million USD | -17.03% |
| 2009 Q3 | 29.71 Million USD | 32.38% |
| 2008 Q2 | 22.81 Million USD | 13.72% |
| 2008 FY | - USD | 30.6% |
| 2008 Q3 | 25.82 Million USD | 13.19% |
| 2008 Q4 | 19.98 Million USD | -22.64% |
| 2008 Q1 | 20.06 Million USD | 153.63% |
| 2007 Q2 | 21.22 Million USD | 21.97% |
| 2007 FY | - USD | 85.1% |
| 2007 Q1 | 17.4 Million USD | 0.0% |
| 2007 Q3 | 21.74 Million USD | 2.47% |
| 2007 Q4 | 7.91 Million USD | -63.62% |
| 2006 FY | - USD | 18.11% |
| 2006 Q2 | 8.23 Million USD | -29.69% |
| 2006 Q1 | 11.7 Million USD | 46.91% |
| 2006 Q3 | 8.01 Million USD | -2.62% |
| 2005 Q2 | 8.4 Million USD | 10.95% |
| 2005 Q4 | 7.96 Million USD | -2.57% |
| 2005 Q1 | 7.57 Million USD | 19.95% |
| 2005 FY | - USD | 4.8% |
| 2005 Q3 | 8.17 Million USD | -2.63% |
| 2004 Q2 | 6.2 Million USD | -7.97% |
| 2004 FY | - USD | -0.2% |
| 2004 Q4 | 6.31 Million USD | -11.82% |
| 2004 Q1 | 6.74 Million USD | -8.34% |
| 2004 Q3 | 7.15 Million USD | 15.38% |
| 2003 Q2 | 7.76 Million USD | -10.05% |
| 2003 Q3 | 3.96 Million USD | -21.36% |
| 2003 Q4 | 7.32 Million USD | 22.2% |
| 2003 Q1 | 10.57 Million USD | 24.46% |
| 2003 FY | - USD | 10.09% |
| 2002 Q3 | 6.54 Million USD | 48.43% |
| 2002 Q4 | 6.59 Million USD | 6.31% |
| 2002 FY | - USD | 1.16% |
| 2002 Q1 | 8.52 Million USD | 13.2% |
| 2002 Q2 | 3.88 Million USD | -47.87% |
| 2001 Q2 | 8.09 Million USD | 100.14% |
| 2001 Q4 | 7.67 Million USD | -5.56% |
| 2001 Q3 | 7.72 Million USD | -1.93% |
| 2001 Q1 | 7.4 Million USD | -38.61% |
| 2001 FY | - USD | 11.27% |
| 2000 Q2 | 6.43 Million USD | 18.25% |
| 2000 Q1 | 5.62 Million USD | 19.43% |
| 2000 FY | - USD | 97.18% |
| 2000 Q4 | 6.57 Million USD | -11.12% |
| 2000 Q3 | 6.7 Million USD | 14.2% |
| 1999 Q1 | -7.3 Million USD | -62.22% |
| 1999 Q3 | -3.8 Million USD | 2.56% |
| 1999 FY | - USD | 396.23% |
| 1999 Q2 | -3.9 Million USD | 46.58% |
| 1999 Q4 | 4.6 Million USD | 218.42% |
| 1998 Q3 | -25.5 Million USD | -696.88% |
| 1998 Q2 | -3.2 Million USD | 23.81% |
| 1998 Q4 | -4.5 Million USD | 82.35% |
| 1998 FY | - USD | 69.11% |
| 1998 Q1 | -4.2 Million USD | 0.0% |
| 1997 Q2 | -5.3 Million USD | -857.14% |
| 1997 Q3 | 4.3 Million USD | 181.13% |
| 1997 Q4 | -4.2 Million USD | -197.67% |
| 1997 FY | - USD | -515.66% |
| 1997 Q1 | 700 Thousand USD | 106.67% |
| 1996 FY | - USD | 107.02% |
| 1996 Q3 | -10.9 Million USD | -473.68% |
| 1996 Q2 | -1.9 Million USD | -18.75% |
| 1996 Q1 | -1.6 Million USD | 0.0% |
| 1996 Q4 | -10.5 Million USD | 3.67% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 237.07% |
| Prenetics Global Limited | -47.89 Million USD | 711.294% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 17455.424% |
| CareDx, Inc | -89.65 Million USD | 426.562% |
| Exact Sciences Corporation | 41.87 Million USD | -599.174% |
| Exagen Inc. | -19.15 Million USD | 1628.669% |
| Inotiv, Inc. | -26.5 Million USD | 1204.603% |
| Guardant Health, Inc. | -433.3 Million USD | 167.57% |
| Biodesix, Inc. | -37.1 Million USD | 889.117% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 11881.369% |
| Precipio, Inc. | -4.31 Million USD | 6880.593% |
| iSpecimen Inc. | -9.1 Million USD | 3316.114% |
| Natera, Inc. | -383.27 Million USD | 176.39% |
| Aspira Women's Health Inc. | -16.49 Million USD | 1875.429% |
| Standard BioTools Inc. | -54.45 Million USD | 637.646% |
| 23andMe Holding Co. | -291.87 Million USD | 200.312% |
| Castle Biosciences, Inc. | -45.02 Million USD | 750.289% |
| Personalis, Inc. | -96.8 Million USD | 402.443% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 349.042% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 3152.703% |
| OpGen, Inc. | -29.51 Million USD | 1092.125% |
| T2 Biosystems, Inc. | -43.87 Million USD | 767.319% |
| Myriad Genetics, Inc. | -67.8 Million USD | 531.838% |
| ICON Public Limited Company | 1.63 Billion USD | 82.056% |
| NeoGenomics, Inc. | -17.6 Million USD | 1762.895% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 17455.424% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 75.955% |
| MDxHealth SA | -30.46 Million USD | 1060.962% |
| Psychemedics Corporation | -251 Thousand USD | 116747.809% |
| Illumina, Inc. | -608 Million USD | 148.156% |
| Check-Cap Ltd. | -17.64 Million USD | 1758.938% |
| Twist Bioscience Corporation | -176.7 Million USD | 265.692% |
| DarioHealth Corp. | -53.49 Million USD | 647.325% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 728.944% |
| Sera Prognostics, Inc. | -35.28 Million USD | 929.728% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 3092.252% |
| OPKO Health, Inc. | -65.51 Million USD | 546.892% |
| Medpace Holdings, Inc. | 363.15 Million USD | 19.377% |
| Neogen Corporation | 182.59 Million USD | -60.345% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 3423.07% |
| Prenetics Global Limited | -47.89 Million USD | 711.294% |
| Mainz Biomed B.V. | -25.01 Million USD | 1270.619% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 3937.65% |
| Trinity Biotech plc | -24.09 Million USD | 1314.98% |
| Neuronetics, Inc. | -22.75 Million USD | 1386.462% |
| Sotera Health Company | 514.14 Million USD | 43.053% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 3937.65% |